Diamyd Medical

May 04, 2020

Promising Findings From the First Part of a Clinical Trial With Remygen®

Apr 24, 2020

Japan Grants Patent for Intralymphatic Administration of the Diabetes Vaccine Diamyd®

Dec 12, 2019

Significant Effect of Diamyd® in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials

Oct 15, 2019

Diamyd Medical Enters Agreement for Intralymphatic Diamyd ® Trial in LADA

Sep 09, 2019

Feasibility Study Supports the use of Intralymphatic Injections of Diamyd®

Jun 04, 2019

New Interim Report at 30 Months and After Extra Injection Supports Long-term Effect of Intralymphatic Diamyd®

May 29, 2019

The Swedish Medical Products Agency Approves New Treatment Arm With Remygen® and Alprazolam in Phase I/II Trial ReGenerate-1

Mar 26, 2019

Diamyd Medical Announces Strategic Activities for 2019 and 2020

Dec 06, 2018

Diamyd Medical Raises SEK 58.4 Million in Funds Through Redemption of Warrants

Oct 23, 2018

New Immunological Results That Support Intralymphatic Treatment With Diamyd® to be Presented at the Immunology of Diabetes Society Congress